Gao Zhan, Fu Hong-Juan, Xue Ju-Jun, Wu Zhi-Xuan, Zhao Li-Bo
Department of Elderly Neurology, Heilongjiang Hospital, Zhongshan Road No. 82, Xiangfang District, Harbin, 150000, People's Republic of China.
Mol Biol Rep. 2014 Jul;41(7):4463-74. doi: 10.1007/s11033-014-3317-0. Epub 2014 Mar 5.
We conducted this meta-analysis of relevant case-control studies to investigate the relationships between genetic polymorphisms in VDR, ESR1 and ESR2 genes to the susceptibility of Parkinson's disease (PD). A search on electronic databases without any language restrictions was conducted: MEDLINE (1966-2013), the Cochrane Library Database (Issue 12, 2013), EMBASE (1980-2013), CINAHL (1982-2013), Web of Science (1945-2013) and the Chinese Biomedical Database (1982-2013). Meta-analysis was performed using the STATA statistical software. Crude odds ratio (OR) with their 95% confidence interval (95% CI) was calculated. Fourteen case-control studies with a total of 3,689 PD patients and 4,627 healthy subjects were included in our meta-analysis. The results of our meta-analysis demonstrated that the VDR genetic polymorphisms might be closely related to increased risks of PD (allele model: OR = 1.18, 95% CI 1.09-1.29, P < 0.001; dominant model: OR = 1.37, 95% CI 1.16-1.63, P < 0.001; respectively), especially for the polymorphisms rs7976091 and rs10735810. Our findings also illustrated that ESR1 genetic polymorphisms might increase the risk of PD (allele model: OR = 1.56, 95% CI 1.17-2.07, P = 0.002; recessive model: OR = 1.93, 95 % CI 1.33-2.80, P < 0.001; homozygous model: OR = 1.35, 95% CI 1.02-1.79, P = 0.038; heterozygous model: OR = 2.04, 95% CI 1.36-3.07, P = 0.001; respectively), especially for the polymorphisms rs2234693 and rs9340799. Furthermore, we found significant correlations of ESR2 genetic polymorphisms with the risk of PD (allele model: OR = 1.78, 95% CI 1.19-2.67, P = 0.005; recessive model: OR = 1.93, 95% CI 1.15-3.27, P = 0.014; homozygous model: OR = 1.77, 95% CI 1.09-2.89, P = 0.022; heterozygous model: OR = 1.88, 95% CI 1.08-3.27, P = 0.025; respectively), especially for the rs1256049 polymorphism. Our meta-analysis suggests that genetic polymorphisms in VDR, ESR1 and ESR2 genes may contribute to increased risks for PD.
我们开展了这项针对相关病例对照研究的荟萃分析，以探究维生素D受体（VDR）、雌激素受体1（ESR1）和雌激素受体2（ESR2）基因的遗传多态性与帕金森病（PD）易感性之间的关系。我们在无任何语言限制的电子数据库中进行了检索：医学文献数据库（MEDLINE，1966 - 2013年）、考克兰图书馆数据库（2013年第12期）、荷兰医学文摘数据库（EMBASE，1980 - 2013年）、护理学与健康领域数据库（CINAHL，1982 - 2013年）、科学引文索引数据库（Web of Science，1945 - 2013年）以及中国生物医学数据库（1982 - 2013年）。使用STATA统计软件进行荟萃分析。计算了粗比值比（OR）及其95%置信区间（95%CI）。我们的荟萃分析纳入了14项病例对照研究，共计3689例PD患者和4627名健康受试者。我们荟萃分析的结果表明，VDR基因多态性可能与PD风险增加密切相关（等位基因模型：OR = 1.18，95%CI 1.09 - 1.29，P < 0.001；显性模型：OR = 1.37，95%CI 1.16 - 1.63，P < 0.001），尤其是rs7976091和rs10735810多态性。我们的研究结果还表明，ESR1基因多态性可能增加PD风险（等位基因模型：OR = 1.56，95%CI 1.17 - 2.07，P = 0.002；隐性模型：OR = 1.93，95%CI 1.33 - 2.80，P < 0.001；纯合子模型：OR = 1.35，95%CI 1.02 - 1.79，P = 0.038；杂合子模型：OR = 2.04，95%CI 1.36 - 3.07，P = 0.001），尤其是rs2234693和rs9340799多态性。此外，我们发现ESR2基因多态性与PD风险存在显著相关性（等位基因模型：OR = 1.78，95%CI 1.19 - 2.67，P = 0.005；隐性模型：OR = 1.93，95%CI 1.15 - 3.27，P = 0.014；纯合子模型：OR = 1.77，95%CI 1.09 - 2.
